Hansa Biopharma announces long term follow-up data that demonstrates 2-year graft survival of 89% after imlifdase treatment and transplantation

Two poster sessions were highlighted at the Cutting Edge of Transplantation summit 2020. Balancing equity and utility in the face of an organ shortage

Lund, Sweden March 6, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases today announced that two posters sessions were hightlighted at the Cutting Edge of Transplantation summit 2020, Thursday March 5th.

A poster with Professor Stanley Jordan, Professor at Cedars Sinai in Los Angeles and Dr. Tomas Lorant, VP and senior medical director of R&D,, Hansa Biopharma as the lead authors on data from “Long-term Outcomes of Sensitized and Crossmatch-Positive Kidney Transplanted Patients after Desensitization with Imlifidase” was presented.

The poster highlights that 43 (93%) of the 46 transplanted patients had a functioning graft after 6 months. 3 graft losses occurred in the crossmatch positive group leaving 36 (92%) of these 39 patients with a functioning graft at 6 months. No further graft losses occurred up to 2 years after transplantation. 2-year death censored graft survival was 24 out of 27 patients (89%), and overall graft survival was 24 of 30 patients (80%).

The kidney function assessment demonstrated that 28 (87%) of the 32 patients with data, and 23 (88%) of the 26 crossmatch positive patients, had a well functioning kidney at 6 months.

In a second poster session authored by Darren Stewart, United Network for Organ Sharing, Joshua Lee and Kristoffer Sjöholm both Hansa Biopharma “The Impact of a Positive Crossmatch on KAS Patients and Organs” was presented

The presentation highlights that reallocating kidneys due to postive crossmatch affects the refused organ by significantly increasing cold ischemia time and the eventual discard of approximately 25 kidneys annually. Patients refusing an organ due to a positive crossmatch had longer waiting times and a significant number ended up dying or being delisted.

Furthermore, fewer patients with cPRA ≥99.9 who experienced a postive crossmatch refusal, received a transplant (30%) compared to other postive crossmatch refusal waitlist patients (45%). It was concluded that technologies and therapies to reduce crossmatch refusals could potentially have a positive impact on patients and kidney allocation.

Christian Kjellman, CSO and COO at Hansa Biopharma comments, 
“We are very exited about how imlifidase potentially can increase the access to transplantation and that the long term follow up data is in line with best expectations in this group of challenging patients with a very high medical need”.

All abstracts from the Cutting Edge of Transplantation can be found on Amercan Society of Transplantation web at www.myast.org

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for marketing authorization by EMA. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.